IW-601 / ImmuneWalk Therapeutics - LARVOL DELTA

IW-601, a first-in-class monoclonal antibody targeting myeloid cells is safe and well tolerated. Pharmacodynamic assessments provide mechanistic validation; Results from IW-601-001 a first-in-human Phase 1 Single Ascending Doses study (EULAR 2025) - "Single ascending doses of subcutaneous IW-601 up to a dose of 10 mg/kg were safe and well tolerated in healthy subjects. The PK profile shows dose-proportionality and long half-life which is expected to allow subcutaneous dosing once every 3-4 weeks. In vivo PD data provide mechanistic validation for IW-601."

P1 data • PK/PD data • Dermatology • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis